Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alterity Therapeutics Ltd ADR (NQ: ATHE ) 1.170 +0.020 (+1.74%) Streaming Delayed Price Updated: 3:54 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Alterity Therapeutics Ltd ADR < Previous 1 2 Next > Appendix 4C – Q1 FY25 Quarterly Cash Flow Report October 31, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 October 14, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting October 11, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® October 02, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer September 30, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® September 23, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Appendix 4C – Q4 FY24 Quarterly Cash Flow Report July 31, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Present at MST Financial Webinar July 24, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy July 17, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar June 12, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study May 29, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review May 08, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Appendix 4C – Q3 FY24 Quarterly Cash Flow Report April 30, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia April 29, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting April 17, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 April 10, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund March 26, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting February 20, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review February 06, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week January 29, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones January 22, 2024 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer December 21, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress December 04, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease December 04, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy November 27, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 November 16, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy November 08, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Appendix 4C – Q1 FY24 Quarterly Cash Flow Report October 30, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder August 31, 2023 From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s August 23, 2023 New Patent Covers Over 150 Novel Compounds From ALTERITY THERAPEUTICS LIMITED Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
